Is Tirzepatide the Same as Mounjaro?

Key takeaways

• Tirzepatide = the molecule. Mounjaro = Eli Lilly’s brand. Same drug.
• Zepbound is the same molecule branded for weight management.
• Tirzepatide is a dual GIP/GLP-1 receptor agonist — semaglutide targets GLP-1 only.
• In head-to-head trials tirzepatide produced greater weight loss than semaglutide.
• Prescription-only in the UK, available via NHS for specific criteria and privately otherwise.

Is tirzepatide the same as Mounjaro?

Yes. This is a naming convention, not a pharmacological distinction. Every licensed medicine has an
international non-proprietary name — the generic molecule name — and one or more brand names given by the
companies marketing it.

Tirzepatide is the non-proprietary name. Mounjaro is the brand under which Eli Lilly markets it for
type 2 diabetes. Zepbound is the brand under which the same molecule is marketed for chronic weight
management in some territories. Three names, one compound.

Is tirzepatide stronger than Ozempic?

In the trials that compared them directly, yes — and the reason is mechanistic. Ozempic contains
semaglutide, which activates the GLP-1 receptor. Tirzepatide activates both the GLP-1 receptor and the
GIP receptor.

SURPASS-2 (Frías et al., 2021) compared tirzepatide against semaglutide 1mg in type 2 diabetes and
found greater reductions in both HbA1c and body weight across tirzepatide doses. SURMOUNT-1 (Jastreboff
et al., 2022) reported mean weight reduction of up to 20.9% at the highest tirzepatide dose over 72 weeks
in people with obesity.

Is tirzepatide available in the UK?

Yes, as a prescription-only medicine. Mounjaro is licensed in the UK and NICE has issued guidance
covering its use for type 2 diabetes and, separately, for weight management within defined eligibility
criteria.

NHS access is rationed against those criteria. Private prescription through a registered pharmacy is
the other lawful route. Either way it requires a prescriber, because it is a prescription-only medicine
and dose escalation needs clinical oversight.

What are the negative side effects of tirzepatide?

Gastrointestinal effects dominate and are usually worst during dose escalation: nausea, vomiting,
diarrhoea, constipation and reduced appetite. These typically ease as the dose stabilises.

Less common but more serious concerns include pancreatitis, gallbladder disease associated with rapid
weight loss, and — the one most relevant to anyone training — loss of lean mass alongside fat.

That last point deserves emphasis. A substantial fraction of weight lost on GLP-1 and dual agonists is
lean tissue, and appetite suppression that profound tends to reduce protein intake at exactly the moment
it matters most. Anyone using these compounds while training should be deliberately tracking protein
rather than eating intuitively.

What the research actually shows

SURMOUNT-1 randomised 2,539 adults with obesity to tirzepatide or placebo for 72 weeks, reporting mean
weight reductions of 15.0%, 19.5% and 20.9% at 5mg, 10mg and 15mg respectively, against 3.1% for placebo.

Those are unusually large effect sizes for a pharmacological weight-loss intervention. They were also
achieved in a supervised trial population with structured dose escalation and lifestyle support — not in
lean individuals self-administering for cosmetic purposes, which the trials did not study.

Practical summary

If a supplier lists “tirzepatide” and another lists “Mounjaro,” they are offering the same molecule.
Compare on documented purity and batch testing rather than on the name.

Anyone comparing the tirzepatide and semaglutide categories should understand these are
prescription-only medicines requiring dose titration and monitoring, and that the lean-mass question makes
protein intake and resistance training more important on these compounds, not less.

Information only, not medical advice. Tirzepatide is a prescription-only medicine in
the UK.

Frequently asked questions

Is Mounjaro the same as Ozempic?

No. Mounjaro is tirzepatide; Ozempic is semaglutide. Different molecules with different receptor
targets.

Does weight return after stopping tirzepatide?

Generally yes. Trial data shows substantial regain after discontinuation, because appetite returns. These
are closer to ongoing therapy than to a finite course.

Can tirzepatide be used purely for cosmetic weight loss?

It is licensed for diabetes and for obesity within defined criteria. Use outside those criteria is
off-licence and still requires a prescriber.